CASTRO-B - Study on CRP Apheresis in STROke Patients in Berlin
- Conditions
- Stroke, Ischemic
- Interventions
- Device: CRP apheresis
- Registration Number
- NCT03884153
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
This study explores the use of CRP level reduction in patients after suffering from acute ischemic stroke. Using selective CRP-apheresis, the investigators aim to reduce the secondary inflammatory tissue damage in the course of infarction maturation using infarction growth in MRI as the primary outcome as a surrogate.
- Detailed Description
C-reactive protein (CRP) is an acute-phase protein binding to phosphocholine, thereby marking damaged tissue. This in turn activates the complement system and the cellular immune system engaging the unspecific immune system in an inflammatory tissue-degrading reaction. Such a pattern is observed in ischemic stroke, and elevated CRP levels can be measured in stroke survivors' sera. Several observational studies reproduced higher CRP levels with negative outcome in stroke. In another vascular model disease, myocardial infarction, selective CRP apheresis reduced infarct size in humans. The investigators therefore designed this pilot study to explore the effects of selective CRP reduction in ischemic stroke patients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
- Age 18 - 85 years
- Informed consent signed by patient
- Patients with acute ischemic stroke in the Arteria cerebri media (MCA) territory within 36 hours of event
- Acute MRI with evidence of infarction
- NIHSS ≥ 4
- CRP > 5 mg/l
- Withdrawal of consent
- Systolic blood pressure <100 mmHg before the apheresis
- Blood pressure relevant extra- and intracranial stenoses (NASCET 70)
- Apheresis contraindication
- Participation in other interventional studies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CRP apheresis CRP apheresis CRP apheresis by means of selective apheresis using the "PentraSorb"-CRP adsorber
- Primary Outcome Measures
Name Time Method Infarct growth 5 ± 1 days after infarction Infarct growth measured via DWI-FLAIR volume change
- Secondary Outcome Measures
Name Time Method Infarct growth 90 ± 14 days after infarction Infarct growth measured via diffusion-weighted imaging (DWI)-FLAIR volume change
Functional Outcome 90 ± 14 days after infarction Modified ranking scale (mRS) score - ranging from 0-6 with higher scores signifying worse outcome no subscales
Quality of Life after Stroke via Stroke Impact Scale (SIS) 90 ± 14 days after infarction Stroke Impact Scale - Stroke Impact Scale (SIS) - measures different aspects of the overall impact of stroke on the patients' health and quality of life with different subscales addressing different domains:
* physical problems
* memory and thinking
* mood and emotions
* communication
* daily activities
* mobility
* motor impairment hand
* participation
* overall recovery higher values represent better outcomeIncidence of Complications 90 ± 14 days after infarction Composite frequency of Complications within the time frame
Stroke Severity 5 ± 1 days after infarction National Institute of Health Stroke Scale (NIHSS) score - ranging from 0-42 - higher values represent a worse outcome
Dependency 90 ± 14 days after infarction Barthel Index (BI) - ranging from 0-100 with higher scores signifying better outcome; no subscales
Cognitive Impairment 90 ± 14 days after infarction Montreal Cognitive Assessment (MoCA) - ranging from 0-30 with higher scores signifying better outcome; no subscales
Trial Locations
- Locations (1)
Zentrum für Schlaganfallforschung (CSB) / Klinik für Neurologie mit Experimenteller Neurologie der Charité
🇩🇪Berlin, Germany